Regulatory T cells

Low-Dose Interleukin-2 in Newly Diagnosed Type 1 Diabetes: Insights from the DIABIL-2 Phase 2b Trial

By MedXY 10/05/2026

The DIABIL-2 trial evaluated low-dose IL-2 therapy for preserving β-cell function in new-onset type 1 diabetes. Despite marked Treg expansion and good safety, IL-2 did not significantly preserve insulin secretion compared to placebo.

Hematology-Oncology news

Harnessing Expanded Antigen-Specific Donor Regulatory T Cells to Prevent GVHD in Allogeneic Hematopoietic Cell Transplantation

By MedXY 10/01/2026

A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-allogeneic hematopoietic cell transplantation.

Hematology-Oncology news

Harnessing Antigen-Specific Donor Regulatory T Cells to Prevent GVHD in Allogeneic Hematopoietic Cell Transplantation

By MedXY 09/30/2026

This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with durable in vivo persistence.

Gastroenterology news Oncology

SPP1-Positive Macrophages Shape Immunosuppression in Colorectal Cancer Lymph Nodes

By MedXY 06/17/2026

Single-cell profiling of colorectal cancer lymph nodes revealed an SPP1–CD44–NF-κB1 pathway that promotes CD137+ regulatory T-cell maturation and may be therapeutically targetable.

Cardiology Clinical Updates news

Orchestrating Cardiac Repair: The CCL1-CCR8 Axis as a Master Regulator of Regulatory T Cell Recruitment Post-Myocardial Infarction

By MedXY 03/01/2026

This review explores the discovery of a two-phase specialization process where CCR8+ regulatory T cells, recruited via the macrophage-derived CCL1 axis, mitigate inflammation and promote cardiac repair following myocardial infarction.

Allergy & Immunology Neurology news

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS

By MedXY 12/31/2025

A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to traditional autologous cell therapies.

Allergy & Immunology Clinical Updates Dermatology news

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

By MedXY 12/06/2025

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomarkers and disease heterogeneity in treatment response.

Dermatology news

Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid

By MedXY 12/06/2025

A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, supporting further randomized evaluation.

Allergy & Immunology Neurology news

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

By MedXY 12/06/2025

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–moderate AD.

news Rheumatology

Guardians Within: Unveiling the Nobel-Winning Discovery of Regulatory T Cells and Their Crucial Role in Immune Balance

By MedXY 10/06/2025

The 2025 Nobel Prize honors the groundbreaking discovery of regulatory T cells (Tregs), key immune modulators that maintain tolerance and prevent autoimmunity, inspiring new therapies for autoimmune disease, transplantation, and cancer.

Allergy & Immunology Internal Medicine news

Guardians Within: The Nobel-Winning Discovery of Regulatory T Cells and Their Role in Immune Balance

By MedXY 10/06/2025

The 2025 Nobel Prize in Physiology or Medicine honors groundbreaking work on regulatory T cells, revealing how the immune system avoids self-attack while combating threats, paving the way for novel therapies in autoimmune and transplant medicine.